A Phase 3 interventional study of Botulinum toxin type A and Botulinum toxin type A in Chronic Migraine, sponsored by Ipsen. Active, not recruiting at 120 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Ipsen · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing botulinum toxin type A in Migraine Disorders — 6 open to participants now, 10 under way, 5 of them phase 3. botulinum toxin type A · Migraine Disorders.
Among the 39 studies testing botulinum toxin type A in Migraine Disorders, this one is the 5th largest by enrollment, is one of 3 that started in 2023, is one of 13 in phase 3, and was the 32nd registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 39 studies testing botulinum toxin type A in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–65
Naval Medical Center Camp Lejeune · Sites in United States
Ages 18–89
Assiut University
Ages 18–65
Assiut University
Ages 18–65
Beni-Suef University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2003; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 759 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 70 across the 39 interventional studies. Of the 25 that completed or were terminated, 17 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 39 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 4 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies testing botulinum toxin type A in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
| NCT07837570Assiut UniversityComparison of the Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 39 studies testing botulinum toxin type A in Migraine Disorders, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine.
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound.
Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache days.
Migraines are caused by a series of events which cause the brain to get stimulated/activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers.
The study will consist of 3 periods:
A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders.
The injections will contain either a dose "A" or dose "B" of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits.
There will be 3 in person visits and 4 remote visits.
Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations.
They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria :
Within 24 weeks
Within 12 weeks
Within 4 weeks
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive four treatment cycles, each separated by an interval of 12 weeks. Double-blind placebo-controlled (DBPC) Phase: Dysport® dose "A" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)
Biological: Botulinum toxin type A
Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Dysport® dose "B" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)
Biological: Botulinum toxin type A
Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Placebo dose "A" administered intramuscularly on Day 1 and Week 12 Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)
Other: Placebo · Biological: Botulinum toxin type A
Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Placebo dose "B" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48).
Other: Placebo · Biological: Botulinum toxin type A
Dose "A" Unit/Injection (U/I), Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.
Also known as: Dysport®
Dose "B" U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections.
Also known as: Dysport®
"0" U/I, IM on Day 1 and Week 12 with a total of 2 injections.
Dose "A" U/I, IM at Week 24 and Week 36 with a total of 2 injections.
Also known as: Dysport®
Dose "B" U/I, IM at Week 24 and Week 36 with a total of 2 injections.
Also known as: Dysport®
Change from baseline at week 24 in monthly migraine days (MMD)
The monthly migraine days (MMD) is assessed by eDiary, completed every day by the participant, to evaluate the efficacy of Dysport® compared to placebo.
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Change from baseline in MMD of ≥50%
The monthly migraine days (MMD) is assessed by a daily eDiary.
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Change from baseline in MMD of ≥75%
The monthly migraine days (MMD) is assessed by a daily eDiary.
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Cumulative number of MMD
The cumulative number of monthly migraine days (MMD) is assessed by a daily eDiary.
Time frame: From Day 1 to Week 24
Change from baseline in MMD of moderate or severe intensity
The intensity of MMD is assessed by a daily eDiary.
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Change from baseline in the number of MMD over the last 12 weeks prior to Week 24
The monthly migraine days (MMD) is assessed by a daily eDiary.
Time frame: From Week 13 - 24
Change from baseline in monthly headache days (MHD) of moderate or severe intensity
The intensity of monthly headache days (MHD) is assessed by a daily eDiary.
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Change from baseline in MHD of moderate or severe intensity of ≥50%
The intensity of monthly headache days (MHD) is assessed by a daily eDiary.
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Change from baseline in MHD of moderate or severe intensity of ≥75%
The intensity of monthly headache days (MHD) is assessed by a daily eDiary.
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Cumulative number of MHD of moderate or severe intensity
The cumulative number of monthly headache days (MHD) is assessed by a daily eDiary.
Time frame: From Day 1 to Week 24
Change from baseline in the number of days per month of acute migraine medication intake
The acute migraine specific medication intake will be recorded in the daily eDiary. Acute migraine medication is defined as triptan, ergotamine, gepant, or ditan.
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Headache medication overuser (yes, no)
The headache medication overuse will be assessed by a concomitant medication log completed at each visit and acute medication taken to treat acute attack will be recorded in the daily eDiary. The headache medication overuse is defined as a participant with ≥10 days/month if ergotamine, triptan, gepant, ditan, opioid or combination analgesic, or ≥15 days/month if non-opioid analgesic (such as paracetamol, aspirin, NSAID)
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Use of acute migraine medication (yes or no)
The use of acute migraine medication will be recorded in the daily eDiary.
Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Patient's Global Impression of Change (PGIC) score
The PGIC will be assessed by a questionnaire (7-point scale, score of 1 indicates very much improved and score of 7 indicates very much worse)
Time frame: At Weeek 12 and Week 24
Change from baseline of ≥1 and ≥2 grades in PGIC score
The PGIC will be assessed by a questionnaire (7-point scale, score of 1 indicates very much improved and score of 7 indicates very much worse)
Time frame: At Weeek 12 and Week 24
Change from baseline in role function restrictive (RFR) domain of Migraine Specific Quality of Life (MSQ) Questionnaire
The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)
Time frame: At Weeek 12 and Week 24
Change from baseline in role function-preventive (RFP) domain of MSQ Questionnaire
The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)
Time frame: At Week 12 and Week 24
Change from baseline in emotional function (EF) domain of MSQ Questionnaire
The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)
Time frame: At Week 12 and Week 24
Change from baseline in total MSQ score
The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)
Time frame: At Weeek 12 and Week 24
Change in MSQ score to the minimally important change (MIC) thresholds
The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)
Time frame: At Weeek 12 and Week 24
Change from baseline in total 6-item Headache Impact Test (HIT-6) score
The HIT-6 will be assessed by a questionnaire (scores range from 36-78 and higher scores indicate a greater impact of headache on subject's life)
Time frame: At Week 12 and Week 24
Change from baseline in HIT-6 score to MIC thresholds
The HIT-6 will be assessed by a questionnaire (scores range from 36-78 and higher scores indicate a greater impact of headache on subject's life)
Time frame: At Weeek 12 and Week 24
Change from baseline in Short Form 12 (SF-12) Questionnaire score
The SF-12 will be assessed by a questionnaire (scores range from 0-100, with higher scores indicating better functioning)
Time frame: At Weeek 12 and Week 24
Chronic migraine status
Chronic migraine status will be assessed by the daily eDiary and defined as number of participants with ≥15 MHD and ≥8 MMD
Time frame: At Week 24 (Week 21-24)
Time to onset of effect
Time to onset of effect is defined as the first time point post randomisation where MMD is reduced from baseline ≥50%
Time frame: From first time point post randomisation to Week 24
Incidence of Treatment emergent adverse event (TEAEs)
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to Week 24
Percentage of Participants with clinically significant changes in vital signs
Percentage of participants with clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.
Time frame: From baseline up to Week 24
Percentage of participants with clinically significant laboratory parameters (blood chemistry, haematology)
Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will graded by the investigator.
Time frame: From baseline up to Week 24
Treatment-emergence of suicidal ideation/suicidal behaviour
It will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) questionnaire that consists of 4 subscales: 1. Ideation severity subscale: questions answered yes/no, severity of ideation scored 1-5 with 5 being most severe 2. Intensity of ideation subscale : scores range from 2-25 with higher scores indicating more severe intensity of ideation. 3. Suicide behaviour subscale:4 types of suicidal behaviours are scored yes/no 4. Behaviour Lethality subscale: actual lethality/medical damage scores 0-5, with 5 being most severe ( death) and potential lethality scores 0-2 with 2 being more potentially lethal.
Time frame: From baseline up to Week 24
Percentage of participants with binding antibodies to Dysport®
Presence of binding antibodies will be assessed using a validated method of electrochemiluminescence assay (ECLA).
Time frame: At Week 24
Percentage of participants with neutralising antibodies to Dysport®
It will be performed only for confirmed positive samples with ECLA (confirmation of the presence of binding antibodies). Presence of neutralizing antibodies will be assessed using a validated cell-based assay (CBA).
Time frame: At Week 24
Showing the first 100 of 120 sites across 9 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in May 2026, 31 months.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 31 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A